Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Guselkumab for moderate to severe psoriasis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Psoriasis is a skin condition that causes the skin to look red and flaky, with crusty patches of skin covered with silvery scales. These patches of skin are often sore and cause itching. Common areas for psoriasis patches to occur are the elbows, knees, scalp and lower back.
The treatment of psoriasis is often successful, but does not completely cure the condition. Psoriasis usually comes and goes so there are times when a patient who has psoriasis may feel well, but other times when the condition flares up and causes the patient a lot of discomfort. As psoriasis is a condition of the skin, some patients may also feel quite upset about the way their skin looks.
Guselkumab is a new drug for the treatment of psoriasis which is injected under the skin. Some studies have suggested guselkumab may be safe and helpful in improving this skin condition.
If guselkumab is licensed for use in the UK, it could be a new treatment option for patients with psoriasis that may work and be more convenient for patients, and cause fewer side effects than current treatments. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Psoriasis Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000426 Date abstract record published 04/03/2016 |